24 February 2016 in Journal of Cellular and Molecular Medicine
Injuries to ligaments are common, painful and debilitating, causing joint instability and impaired protective proprioception sensation around the joint. Healing of torn ligaments usually fails to take place, and surgical replacement or reconstruction is required. Previously, we showed that in vivo application of the recombinant human amelogenin protein (rHAM+) resulted in enhanced healing of the tooth‐supporting tissues. The aim of this study was to evaluate whether amelogenin might also enhance repair of skeletal ligaments. The rat knee medial collateral ligament (MCL) was chosen to prove the concept. Full thickness tear was created and various concentrations of rHAM+, dissolved in propylene glycol alginate (PGA) carrier, were applied to the transected MCL. 12 weeks after transection, the mechanical properties, structure and composition of transected ligaments treated with 0.5 μg/μl rHAM+ were similar to the normal un‐transected ligaments, and were much stronger, stiffer and organized than control ligaments, treated with PGA only. Furthermore, the proprioceptive free nerve endings, in the 0.5 μg/μl rHAM+ treated group, were parallel to the collagen fibres similar to their arrangement in normal ligament, while in the control ligaments the free nerve endings were entrapped in the scar tissue at different directions, not parallel to the axis of the force. Four days after transection, treatment with 0.5 μg/μl rHAM+ increased the amount of cells expressing mesenchymal stem cell markers at the injured site. In conclusion application of rHAM+ dose dependently induced mechanical, structural and sensory healing of torn skeletal ligament. Initially the process involved recruitment and proliferation of cells expressing mesenchymal stem cell markers.
3 October 2023 in Bone & Joint Research
Aims: Cartilage injuries rarely heal spontaneously and often require surgical intervention, leading to the formation of biomechanically inferior fibrous tissue. This study aimed to evaluate the possible effect of amelogenin on the healing process of a large osteochondral injury (OCI) in a rat model.Methods: A reproducible large OCI was created in the right leg femoral trochlea of 93 rats. The OCIs were treated with 0.1, 0.5, 1.0, 2.5, or 5.0 μg/μl recombinant human amelogenin protein (rHAM+) dissolved in propylene glycol alginate (PGA) carrier, or with PGA carrier alone. The degree of healing was evaluated 12 weeks after treatment by morphometric analysis and histological evaluation. Cell recruitment to the site of injury as well as the origin of the migrating cells were assessed four days after treatment with 0.5 μg/μl rHAM+ using immunohistochemistry and immunofluorescence.Results: A total of 12 weeks after treatment, 0.5 μg/μl rHAM+ brought about significant repair of the subchondral bone and cartilage. Increased expression of proteoglycan and type II collagen and decreased expression of type I collagen were revealed at the surface of the defect, and an elevated level of type X collagen at the newly developed tide mark region. Conversely, the control group showed osteoarthritic alterations. Recruitment of cells expressing the mesenchymal stem cell (MSC) markers CD105 and STRO-1, from adjacent bone marrow toward the OCI, was noted four days after treatment.Conclusion: We found that 0.5 μg/μl rHAM+ induced in vivo healing of injured articular cartilage and subchondral bone in a rat model, preventing the destructive post-traumatic osteoarthritic changes seen in control OCIs, through paracrine recruitment of cells a few days after treatment.Cite this article: Bone Joint Res 2023;12(10):615–623.
24 April 2022 in Minimally Invasive Therapy & Allied Technologies
In non-resectable tumors, chemotherapy is crucial to improve patient survival. However, it is often accompanied by considerable side effects. Targeted delivery of chemotherapy by coupling with iron oxide superparamagnetic nanoparticles (IONP) could potentially increase efficacy while decreasing adverse systemic side effects. We aimed to evaluate the feasibility of targeting nontoxic, biodegradable-IONP into tumors in-vivo by applying an external magnetic field. Subcutaneous colon carcinoma tumors were induced in 35 mice. IONP was injected systemically, followed by suturing of a magnet on top of the tumors for 2–24 h. Tumors and livers were excised and stained for iron to explore IONP localization. Iron staining was evident in 43% and 20% of tumors exposed to magnets for 4 h or 24 h, respectively. No iron was present following 2 h exposure, nor in the control group; however, iron stain in the livers indicates most of the IONP were cleared by the liver 24 h later. We demonstrated the targeting feasibility of IONP to tumor tissue by an external magnetic field. Our data shows successful targeting; however, with low efficacy following systemic injection of the IONP. As such, a paradigm shift is strongly recommended from systemic to locoregional IONP injection to increase targeting efficacy.
18 July 2025 in The FASEB Journal
Previous studies have demonstrated that recombinant human amelogenin protein (rHAM + ) promotes healing of injured articular cartilage, subchondral bone, and skeletal ligaments. Therefore, we speculated that amelogenin may play a role in osteoarthritis (OA) development. Aged amelogenin‐null and wild‐type mice underwent micro‐computed tomography (micro‐CT) and histological analyses to assess OA‐related changes. Additionally, OA was induced in rat knees via destabilization of the medial meniscus, followed by treatment with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) or PGA alone. Magnetic resonance imaging (MRI) and histological analyses were performed. Twenty‐three‐month‐old amelogenin‐null mice exhibited severe OA features, including cartilage loss, joint space narrowing, and osteophyte formation, whereas wild‐type mice showed only mild, age‐related changes. OA pathology was evident in 12‐month‐old amelogenin‐null mice, by increased matrix metalloproteinase‐13 (MMP‐13) and decreased type II collagen expression. In osteoarthritic rats, MRI analyses demonstrated that treatment with rHAM + delayed disease progression and improved OA phenotypes. Twenty‐four weeks posttreatment, the levels of type II collagen increased, while MMP‐13 and type X collagen decreased. MMP‐13 reduction was detected as early as 2 weeks posttreatment, contributing to cartilage preservation. Furthermore, similar to the known effect of rHAM + in acute injuries, recruitment of CD105‐positive mesenchymal stem cells to the cartilage was detected 5 days posttreatment. Lack of amelogenin led to the development of osteoarthritic phenotypes, whereas in the induced osteoarthritis model, a single application of amelogenin inhibited joint deterioration and partially healed osteoarthritic damage compared with the control. These findings highlight the potential of amelogenin as a disease‐modifying agent for OA.